Transient receptor potential melastatin 3

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from TRPM3)

Transient Receptor Potential Melastatin 3 or TRPM3 is a non-selective ion channel permeable to both calcium and magnesium. Impaired activity of TRPM3 function is a potential biomarker for ME/CFS.[1] TRPM3 may also be used to refer to the gene for TRPM3.

Function[edit | edit source]

ME/CFS[edit | edit source]

Notable studies[edit | edit source]

  • 2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment[2] - (Full text)
  • 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[1] - (Full text)
  • 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients[3] - (Abstract)
  • 2016, Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[6] - (Full text)
  • 2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[7] - [http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0859-z (Full text)
  • 2016, Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients[8] - (Full text)
  • 2015, Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients][9] - (Abstract) - small study - 115 people with ME/CFS
  • 2015, Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis[10] - [https://onlinelibrary.wiley.com/doi/10.1111/sji.12388/abstract (Abstract)

News and blogs[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (December 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 25 (14). doi:10.1186/s10020-019-0083-4. ISSN 1076-1551.
  2. ↑ Cabanas, Helene; Muraki, Katsuhiko; Eaton-Fitch, Natalie; Staines, Donald Ross; Marshall-Gradisnik, Sonya (2021). "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment". Frontiers in Immunology. 12: 687806. doi:10.3389/fimmu.2021.687806. ISSN 1664-3224. PMC 8313851. PMID 34326841.
  3. ↑ Cabanas, Helene; Muraki, Katsuhiko; Staines, Donald; Marshall-Gradisnik, Sonya (October 14, 2019). "Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients". Frontiers in Immunology. doi:10.3389/fimmu.2019.02545.
  4. ↑ Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in Natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24 (2). doi:10.1186/s10020-018-0046-1. ISSN 1076-1551. PMC 6092868. PMID 30134818.
  5. ↑ Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  6. ↑ Marshall-Gradisnik, S.M.; Chacko, A.; Johnston, S.; Smith, P.; Nilius, B.; Staines, D.R. (January 1, 2016). "Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients". Immunology and Immunogenetics Insights. 8: III.S37042. doi:10.4137/III.S37042. ISSN 1178-6345.
  7. ↑ Huth, Teilah Kathryn; Staines, Donald; Marshall-Gradisnik, Sonya (April 21, 2016). "ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Journal of Translational Medicine. 14 (1): 97. doi:10.1186/s12967-016-0859-z. ISSN 1479-5876. PMC 4839077. PMID 27098723.
  8. ↑ Nguyen, T.; Staines, D.; Nilius, B.; Smith, P.; Marshall-Gradisnik, S. (May 31, 2016). "Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients". Biological Research. 49 (1): 27. doi:10.1186/s40659-016-0087-2. ISSN 0717-6287. PMC 4888729. PMID 27245705.
  9. ↑ Marshall-Gradisnik, Sonya M.; Smith, Peter; Brenu, Ekua W.; Nilius, Bernd; Ramos, Sandra B.; Staines, Donald R. (January 1, 2015). "Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients". Immunology and Immunogenetics Insights. 7: III.S25147. doi:10.4137/III.S25147. ISSN 1178-6345.
  10. ↑ Huth, T.K.; Brenu, E.W.; Ramos, S.; Nguyen, T.; Broadley, S.; Staines, D.; Marshall‐Gradisnik, S. (2016). "Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis". Scandinavian Journal of Immunology. 83 (1): 44–51. doi:10.1111/sji.12388. ISSN 1365-3083.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

B cell B lymphocyte, or a type of white blood cell, which is involved in the immune response by secreting antibodies to ward off infections. In mammals, they are mostly matured in the bone marrow.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

single nucleotide polymorphism (SNP) - A single nucleotide polymorphism (SNP, pronounced "snip") is a potential genetic mutation that occurs in a single spot in the human genome; a difference in a single DNA building block. SNPs are often represented by an "rs" number, such as "rs53576".

Retrieved from "https://me-pedia.org/w/index.php?title=Transient_receptor_potential_melastatin_3&oldid=242631"